Skip to content
A clinical trial investigating an engineered regulatory T-cell therapy for severe autoimmune conditions has advanced to its second planned dose cohort, following an initial safety assessment.
The Phase 1/2 CHILL study is evaluating QEL-005, a therapy developed by Quell Therapeutics, in people with conditions including rheumatoid arthritis and systemic sclerosis. The Oxford Experimental Medicine Clinical Research Facility and Leeds Teaching Hospitals NHS Trust are among the UK teams involved in recruiting and treating participants.
Regulatory T cells help control immune responses and prevent the body from attacking its own tissues. QEL-005 uses engineered natural regulatory T cells designed to respond to B-cell activity. Researchers are investigating whether this approach could help regulate the inflammation associated with autoimmune disease.
The first dose cohort reported no dose-limiting toxicities, treatment-related adverse events of special interest or serious adverse events. This allowed the study to progress to its next planned dose level. These are early safety findings, rather than evidence that the treatment is effective; further assessment is needed as the trial continues.
The study is notable for bringing an advanced cell therapy into clinical settings beyond oncology and haematology, where much of the early experience with these treatments has been gained. Delivering a cell-based investigational medicine in an immunology pathway requires careful coordination across teams that may not routinely work together on advanced therapy trials.
At participating hospitals, this includes clinical research staff, cellular therapy specialists and clinical trials pharmacy teams. Each has a role in managing the patient pathway and ensuring that the investigational product is handled and administered according to the study protocol.
For laboratory professionals, CHILL highlights the infrastructure behind clinical cell-therapy research. Product identification and traceability, controlled storage and transport, and clear handovers between departments are essential to safe delivery. Consistent sample collection and analysis will also be important as researchers assess safety and investigate biological responses.
The trial remains at an early stage, but its progress offers a useful view of how advanced therapies are moving into new areas of medicine. Alongside the scientific questions about immune regulation, it is helping clinical and laboratory teams build the practical experience needed to evaluate these treatments responsibly.
